ProCE Banner Activity

CME

Focus on Janus Kinase Inhibitors in Rheumatoid Arthritis

Multimedia
In this video module, Gregg J. Silverman, MD, and William F. C. Rigby, MD, discuss the indications, mechanisms of action, and recent pivotal trial data regarding Janus kinase inhibitors in the management of rheumatoid arthritis.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: August 01, 2016

Expiration: July 31, 2017

No longer available for credit.

Share

Faculty

William F. C. Rigby

William F. C. Rigby, MD

Vice Chair, Department of Medicine
Professor of Medicine, Microbiology and Immunology
Rheumatology Section
The Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire

Gregg J. Silverman

Gregg J. Silverman, MD

Professor of Medicine and Pathology
NYU School of Medicine
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Lilly USA

Target Audience

This activity is intended for rheumatologists, internists, primary care physicians, and other clinicians who manage patients with rheumatoid arthritis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Compare the mechanisms of action of new and emerging Janus kinase inhibitors
  • Apply results from clinical data and guideline recommendations regarding Janus kinase inhibitors in the management of rheumatoid arthritis patients now and in the future

Faculty Disclosure

Primary Author

William F. C. Rigby, MD

Vice Chair, Department of Medicine
Professor of Medicine, Microbiology and Immunology
Rheumatology Section
The Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire

William F. C. Rigby, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Lilly, Pfizer, and Roche; fees for non-CME/CE activities from Bristol-Myers Squibb; and funds for research support from AbbVie, Bristol-Myers Squibb, Pfizer, and Roche.

Gregg J. Silverman, MD

Professor of Medicine and Pathology
NYU School of Medicine
New York, New York

Gregg J. Silverman, MD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Pfizer and fees for non-CME services from Bristol-Myers Squibb, Genentech.

Staff Disclosure

Staff

Andrew D. Bowser, ELS, CCMEP

Editorial Director, Hematology/Oncology

Andrew D. Bowser, ELS, CCMEP, has no real or apparent conflicts of interest to report.

Megan K. Murphy, PhD

Scientific Director

Megan Murphy, PhD, has no real or apparent conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.


Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 01, 2016, through July 31, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ knowledge, confidence and competence in the management of patients with rheumatoid arthritis.